Weekly low-dose docetaxel combined with estramustine and dexamethasone for Japanese patients with metastatic castration-resistant prostate cancer

International Journal of Clinical Oncology

Volumn 18, Issue 4, 2013, Pages 704-710

  Hatano, Koji ^a   Nishimura, Kazuo ^b   Nakai, Yasutomo ^a   Yoshida, Takahiro ^a   Sato, Mototaka ^a   Kawashima, Atsunari ^a   Mukai, Masatoshi ^a   Nagahara, Akira ^a   Uemura, Motohide ^a   Oka, Daizo ^a   Nakayama, Masashi ^b   Takayama, Hitoshi ^a   Shimizu, Kiyonori ^c   Meguro, Norio ^c   Tanigawa, Tsuyoshi ^d   Yamaguchi, Seiji ^d   Tsujimura, Akira ^a   Nonomura, Norio ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

^c TOYONAKA MUNICIPAL HOSPITAL   (Japan)

^d OSAKA GENERAL MEDICAL CENTER   (Japan)

Author keywords

Castration resistant prostate cancer; Chemotherapy; Dexamethasone; Docetaxel; Estramustine

Indexed keywords

CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOCETAXEL; ESTRAMUSTINE PHOSPHATE; FLUOROURACIL; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; BONE METASTASIS; BONE PAIN; CANCER PATIENT; CANCER RADIOTHERAPY; CASTRATION RESISTANT PROSTATE CANCER; CUSHINGOID SYNDROME; DEEP VEIN THROMBOSIS; DIABETES MELLITUS; DIARRHEA; DISEASE ASSOCIATION; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EPIPHORA; HEMOGLOBIN BLOOD LEVEL; HOT FLUSH; HUMAN; HYPERGLYCEMIA; JAPAN; LOW DRUG DOSE; LUNG METASTASIS; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MULTIPLE CYCLE TREATMENT; NEUROPATHY; NEUTROPENIA; PERIPHERAL EDEMA; PLEURA EFFUSION; PNEUMONIA; PRIORITY JOURNAL; RESPIRATORY FAILURE; TASTE DISORDER; TREATMENT DURATION; TREATMENT OUTCOME; VISCERAL METASTASIS;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEXAMETHASONE; ESTRAMUSTINE; HUMANS; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; TAXOIDS; TREATMENT OUTCOME;

EID: 84882597678     PISSN: 13419625     EISSN: 14377772     Source Type: Journal    
DOI: 10.1007/s10147-012-0429-1     Document Type: Article

References (30)

1. Tannock IF, de Wit R, Berry WR et al (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351:1502-1512
2. Petrylak DP, Tangen CM, Hussain MH et al (2004) Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351:1513-1520
3. Shimazui T, Kawai K, Miyanaga N et al (2007) Three-weekly docetaxel with prednisone is feasible for Japanese patients with hormone-refractory prostate cancer: a retrospective comparative study with weekly docetaxel alone. Jpn J Clin Oncol 37:603-608
4. Naito S, Tsukamoto T, Koga H et al (2008) Docetaxel plus prednisolone for the treatment of metastatic hormone-refractory prostate cancer: a multicenter Phase II trial in Japan. Jpn J Clin Oncol 38:365-372
5. Ide H, Kikuchi E, Kono H et al (2010) Docetaxel in combination with prednisolone for hormone refractory prostate cancer. Jpn J Clin Oncol 40:79-84
6. Miura N, Numata K, Kusuhara Y et al (2010) Docetaxel-prednisolone combination therapy for Japanese patients with hormone-refractory prostate cancer: a single institution experience. Jpn J Clin Oncol 40:1092-1098
7. Nakagami Y, Ohori M, Sakamoto N et al (2010) Safety and efficacy of docetaxel, estramustine phosphate and hydrocortisone in hormone-refractory prostate cancer patients. Int J Urol 17:629-634
8. Berthold DR, Pond GR, Soban F et al (2008) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol 26:242-245
9. Nishimura K, Nonomura N, Yasunaga Y et al (2000) Low doses of oral dexamethasone for hormone-refractory prostate carcinoma. Cancer 89:2570-2576
10. Hatano K, Nonomura N, Nishimura K et al (2011) Retrospective analysis of an oral combination of dexamethasone, uracil plus tegafur and cyclophosphamide for hormone-refractory prostate cancer. Jpn J Clin Oncol 41:253-259
11. Williams JF, Muenchen HJ, Kamradt JM et al (2000) Treatment of androgen-independent prostate cancer using antimicrotubule agents docetaxel and estramustine in combination: an experimental study. Prostate 44:275-278
12. Petrylak DP, Macarthur R, O'Connor J et al (1999) Phase I/II studies of docetaxel (Taxotere) combined with estramustine in men with hormone-refractory prostate cancer. Semin Oncol 26:28-33
13. Scher HI, Halabi S, Tannock I, Prostate Cancer Clinical Trials Working Group et al (2008) Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 26:1148-1159
14. Chowdhury S, Burbridge S, Harper PG (2007) Chemotherapy for the treatment of hormone-refractory prostate cancer. Int J Clin Pract 61:2064-2070
15. ten Tije AJ, Verweij J, Carducci MA et al (2005) Prospective evaluation of the pharmacokinetics and toxicity profile of docetaxel in the elderly. J Clin Oncol 23:1070-1077
16. Takenaka A, Yamada Y, Kurahashi T et al (2008) Combination chemotherapy with weekly docetaxel and estramustine for hormone refractory prostate cancer in Japanese patients. Int J Urol 15:106-109
17. Matsumoto A, Inoue A, Yokoi S et al (2009) Evaluation of docetaxel plus estramustine in the treatment of patients with hormone-refractory prostate cancer. Int J Urol 16:687-691
18. Leberbauer C, Boulme F, Unfried G et al (2005) Different steroids co-regulate long-term expansion versus terminal differentiation in primary human erythroid progenitors. Blood 105:85-94
19. Armstrong AJ, Garrett-Mayer ES, Yang YC et al (2007) A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX327 study analysis. Clin Cancer Res 13:6396-6403
20. Chao Y, Wu Q, Shepard C et al (2012) Hepatocyte induced re-expression of E-cadherin in breast and prostate cancer cells increases chemoresistance. Clin Exp Metastasis 29:39-50
21. Armstrong AJ, Garrett-Mayer E, Ou Yang YC et al (2007) Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer. J Clin Oncol 25:3965-3970
22. Petrylak DP, Ankerst DP, Jiang CS et al (2006) Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16. J Natl Cancer Inst 98:516-521
23. Saad F, Ruether D, Ernst S et al (2008) The Canadian Uro-Oncology Group multicentre phase II study of docetaxel administered every 3 weeks with prednisone in men with metastatic hormone-refractory prostate cancer progressing after mitoxantrone/prednisone. BJU Int 102:551-555
24. Berthold DR, Pond GR, de Wit R et al (2008) Survival and PSA response of patients in the TAX 327 study who crossed over to receive docetaxel after mitoxantrone or vice versa. Ann Oncol 19:1749-1753
25. Nishimura K, Nonomura N, Satoh E et al (2001) Potential mechanism for the effects of dexamethasone on growth of androgen-independent prostate cancer. J Natl Cancer Inst 93:1739-1746
26. Fizazi K, Le Maitre A, Hudes G et al (2007) Addition of estramustine to chemotherapy and survival of patients with castration-refractory prostate cancer: a meta-analysis of individual patient data. Lancet Oncol 8:994-1000
27. Eymard JC, Priou F, Zannetti A et al (2007) Randomized phase II study of docetaxel plus estramustine and single-agent docetaxel in patients with metastatic hormone-refractory prostate cancer. Ann Oncol 18:1064-1070
28. Caffo O, Sava T, Comploj E et al (2008) Docetaxel, with or without estramustine phosphate, as first-line chemotherapy for hormone-refractory prostate cancer: results of a multicentre, randomized phase II trial. BJU Int 102:1080-1085
29. Nelius T, Klatte T, Yap R et al (2006) A randomized study of docetaxel and dexamethasone with low- or high-dose estramustine for patients with advanced hormone-refractory prostate cancer. BJU Int 98:580-585
30. Machiels JP, Mazzeo F, Clausse M et al (2008) Prospective randomized study comparing docetaxel, estramustine, and prednisone with docetaxel and prednisone in metastatic hormone-refractory prostate cancer. J Clin Oncol 26:5261-5268